

Current Status of Proton Pump Inhibitors in Pharmacotherapy of Diabetes Mellitus

Patil TR^{1*}, Patil ST², Patil S³ and Patil A⁴

¹MD Consultant Physician "Gurukripa" Miraj, India

²MBBS, DGO, Gynecologist, India

³MDS, School of Dental Sciences, Karad, India

⁴ MDS, Oral pathologist Maharashtra, India

Mini Review

Volume 3 Issue 3

Received Date: August 19, 2019

Published Date: September 05, 2019

DOI: 10.23880/ipcm-16000178

***Corresponding author:** Patil TR, Consultant Physician "Gurukripa" Miraj, Maharashtra, India, Email: drpatiltr@gmail.com

Abstract

Diabetes mellitus [DM] is a chronic metabolic disorder with its associated complications. Despite the plethora of available anti diabetic drugs to treat DM search continues to discover newer drugs. Proton pump inhibitors [PPIs] are the drugs which have been tested by researchers in animal models and in clinical set up to treat DM. They appeared to be promising drugs to reduce hyperglycemia. They can be used as supportive drugs along with the primary anti diabetic drugs. PPIs enhance rebound gastrin release, increase beta cell mass and insulin release. They are not hypoglycemic drugs. They reduce blood sugar by increase in gastrin and GLP-1 levels, decrease in ghrelin levels, reduced appetite, delayed gastric emptying and enhanced satiety through action on CNS. PPIs are the inhibitors of organic cation transporters (OCTs) for which metformin is the substrate and hence the plasma levels of metformin are increased. The potential and safety of PPIs in treatment of DM should be evaluated by long term clinical trials.

Keywords: Anti diabetic; Gastrin; Metformin; Proton Pump Inhibitors

Abbreviations: DM: Diabetes Mellitus; PPIs: Proton Pump Inhibitors; OCTs: Organic Cation Transporters.

Introduction

Diabetes mellitus [DM] is a fast growing noninfectious disease which affects the population of both developing and developed countries. It is estimated that by 2025, about 380 million people will be affected by type 2 DM [1]. Type 2 DM is more common which is mainly treated by

oral anti diabetic drugs [2]. Type 2 DM is characterized by progressive pancreatic beta cell failure and peripheral insulin resistance in muscles and fat. It also comprises accelerated lipolysis, incretion resistance or deficiency, increased renal glucose absorption and hyperglycemia and brain insulin resistance. In Type 1 diabetes mellitus, hyperglycemia is due to absolute or relative deficiency of insulin release from pancreatic beta cells [3]. Hence along with other targets for treatment of diabetes mellitus, beta cell regeneration is of utmost importance. Proton pump

inhibitors [PPIs] are the class of drugs which have been tried to achieve the target of beta cell regeneration and increase in beta cell mass.

PPIs are the drugs used to treat acid peptic disease, gastro esophageal reflux disorders; NSAIDS induced gastric mucosal injury, H pylori infection and Zollinger Ellison syndrome [4]. Whenever PPIs are given for long term and along with the reduced acid secretion from stomach they enhance gastrin release as a rebound, feedback phenomenon. Increased acid secretion in response to protein meal is triggered by gastrin release which also secretes pepsin along with HCl in the gastric lumen [5].

Gastrin is a peptide hormone secreted mainly by antral G cells in the form of biologically active gastrin 17 and gastrin 34 [6,7]. Factors which stimulate gastrin secretion are vagal stimulation, rise in intra gastric pH, distention of stomach, and the presence of food mainly protein in nature [8-12]. Small quantity of gastrin is synthesized by certain luminal stimuli and also by the presence of dietary protein and amino acids [12,13]. Gastrin stimulates gastric acid secretion from gastric parietal cells. Gastrin and cholecystokinin bind to gastrin and cholecystokinin B [CCK-B] receptors and promote gastric acid secretion [14-16].

Gastrin is proved to be islet cell growth factor similar to glucagon like polypeptide I [GLP-1] and has trophic effect on beta cell mass [17-19]. Gastrin acts as a growth factor and stimulates gastric cell proliferation [12,20]. It also promotes beta cell neogenesis in pancreatic ductal complex and enhances pancreatic beta cell replication considerably. This helps in the control of raised blood sugar level [21].

Gastrin receptor is a major receptor for gastrin and is expressed abundantly in the entero chromaffin cells of stomach [22]. Gastrin can be called as early incretion hormone as it gets released by oral glucose administration and stimulates the glucose related insulin secretion [23]. PPIs lower blood sugar by enhancing rebound gastrin secretion [24-26]. Based on negative feedback between PPIs and gastrin. PPIs have been tested by researchers to correlate their effect with the control of hyperglycemia in T2 DM [27-29].

The known factors which stimulate beta cells neogenesis from the pancreatic duct cells in vivo and vitro are epidermal growth factor (EGF), keratinocyte growth factor and transforming growth factor alpha (TGF Alfa), GLP-1, and gastrin [30-34]. When gastrin was combined

with EGF, accelerated beta cell mass was observed in streptozotocin induced diabetic rats and alloxan induced diabetic mice which also controlled the hyperglycemia. Adult human islet beta cells from pancreatic duct cells when treated with combination of gastrin and EGF, together they increased functional beta cell mass [35,36]. Both play different roles in the proliferation and differentiation of beta cells. Gastrin induced the expression of transcription factor PDX-1 in the duct cells and helped in differentiation of pancreatic beta cells [19].

When gastrin was combined with GLP-1, increased beta cell mass was found in the diabetic immune deficient mice, in which human beta cells were implanted [37]. Gastrin is proved to be islet cell growth factor like GLP- I and has trophic effect on beta cell mass [17-19]. In animal studies, when gastrin was combined with GLP 1, accelerated beta cell growth and insulin secretion was observed [38]. GLP-1 protects beta cells by reducing apoptosis and by enhancing exogenesis and proliferation. They stimulate ductal cells to transform in to islet cells and also stimulate beta cell regeneration within the islets [39].

When dipeptide peptidase 4 [DPP4] inhibitors were combined with PPIs, rate of restoration of normaglycaemia was almost double than by that of DPP4 inhibitors used alone in diabetic mice [40]. PPIs delay the gastric emptying for solids and the possible underlying mechanism for their delayed emptying could relate to the inhibition of peptic hydrolysis due to inhibited acid dependant peptic activity. Gastric emptying of liquids depends on volume and energy density of intra gastric contents. PPIs modify volume and energy density by reducing gastric acid secretion [41]. Like GLP-1, PPIs are found to slow gastric emptying and decrease post prandial hyperglycemia and fluctuations in blood sugar levels [41,42].


Factors such as gastrointestinal hormones like glucose mimetic insulinotropic peptide (GIP), GLP-1, gastrin and cholecystokinin govern the beta cell turnover [17,39]. Suppressed or decreased gastric acidity acts as a trigger for gastrin release from antral G cells [43]. Gastrin is known to regulate beta cell function [17,25,26,44]. Like GLP1, Gastrin also promote beta cell neogenesis, proliferation, differentiation and increase the mass and eventually reduce blood sugar by improved insulin release [17,36].

PPIs are found to improve parameters of beta cell function such as HOMA-B, BSL, HbA1c, fasting insulin, fasting pro insulin and C peptide levels in the normal and T2DM patients. Pantoprazole was found to improve beta cell function and control hyperglycemia in DM.

Pantoprazole therapy for 12 weeks improved beta cell function by 16.2% in diabetic group and also there was rise in levels of pro insulin, insulin and C peptide and decrease in HbA1c levels [45]. Various other studies had similar observations [25, 26,44]. PPIs therapy increased C peptide which is a known marker of endogenous insulin release.

PPIs could lower blood sugar by enhancing rebound gastrin secretion [17,25,26,44]. PPIs increase gastrin levels by negative feedback mechanism and stimulate beta cell neogenesis, proliferation and enhance insulin release [46-52]. Administration of omeprazole 40 mg daily in healthy

men increased the antral gastrin content [53]. In animal models of type 2 DM, PPIs improved glycemic control as a result of increased gastrin levels and beta cell mass [54]. Clinical studies also demonstrated that PPIs significantly improved glycemic control in type 2 DM patients [26-28, 29,44,55,56]. But some studies did not show improvement in glycemic control [57,58]. PPIs decreased HbA1c levels significantly in type 2 DM patients who had initial high HbA1c and blood sugar levels [29]. As against no significant change in these parameters was observed in those diabetic patients who had reasonably good control of HbA1c and blood sugar levels during the time of study [57,58].



It is possible that gastrin enhances insulin secretion by directly stimulating pancreatic beta cells other than increasing beta cell mass whose increase is mainly observed during pancreatic remodeling. Protein rich meal without being glucose rich increases both circulating gastrin and insulin levels which may be without increasing beta cell mass. This also explains the effect of PPIs on glycemic control which is mediated through gastrin, directly stimulating beta cells and increasing insulin release [7].

Interaction between ghrelin and gastrin is known. Ghrelin plays an important role in appetite regulation and energy homeostasis. Ghrelin has negative correlation with

gastrin as observed in human being. Increased gastrin levels suppress ghrelin release, reduces appetite which helps to improve glycemic control [59].

Possible effect of gastrin on central nervous system needs consideration. Food intake was found to be decreased after intra cerebroventricular injection of gastrin [60]. Diffusion of gastrin in the brain through blood brain barrier [BBB] has got limitations [61]. But it can be possible due to the lack of BBB in circum ventricular organs. The peptide or peptide fragments enter in the brain [62]. Gastrin administered intravenously was found to activate neurons in the several parts of the brain [63]. It was observed that gastrin stimulated neurons of area

postrema which have CCK-B receptors and project to the nucleus tractus solitarius [NTS] [64]. In mouse NTS-proopiomelanocortin neurons in the brain stem govern satiety. Hence it is possible that PPIs induced increased gastrin levels inhibit appetite through their action on central nervous system, possibly gastrin acting via vagal nerve on the brain stem [65].

Recently it was found that gastrin stimulated L cells in the intestine and enhanced GLP-1 secretions. This also contributes for glucose lowering effect of gastrin and PPIs. GLP-1 enhances insulin release, reduces glucagon secretion, reduces gastric emptying and enhances satiety [66].

Metformin is the time tested drug for last 60yrs in the treatment of DM. Transport of metformin in to the cell is governed by organic cation transporters [OCT] 1, 2 and 3 which are expressed specifically in organs like liver, muscles and kidney. Omeprazole, rabeprazole, pantoprazole, and lansoprazole are the potent OCT inhibitors. These PPIs inhibited metformin uptake in the concentration dependent manner by OCTs. PPIs are not the substrates for OCTs. Metformin does not undergo hepatic metabolism. Hence drug interaction by inhibition of OCTs is important. All these PPIs inhibited metformin uptake transport by inhibiting all 3 OCT proteins [67].

PPIs are inhibitors of OCTs. Metformin forms a substrate for OCTs. PPI can affect plasma levels of metformin. Studies done with omeprazole and pantoprazole to observe their effect on metformin pharmacokinetics revealed that these PPIs increased the plasma concentration of metformin. Metformin given alone had its lesser plasma concentration level than when combined with PPIs. Thus PPIs increase plasma metformin levels [68].

Lansoprazole increased mean maximum plasma concentration of metformin and area under plasma concentration time curve. It also prolonged metformin elimination half from 3.9 to 4.5 hours and also decreased its renal clearance by 13% [69].

Metformin when was co-administered with rabeprazole, its plasma concentration was increased by 18.6% and area under curve by 14.5%. Like other PPIs rabeprazole can strongly inhibit the transporting ability of OCTs. It was observed that rabeprazole can strongly inhibit MATE 1 mediated metformin transport in vitro. MATE 1 and OCT 2 are expressed on apical and basal layer of renal tubules abundantly and are responsible for renal excretion of metformin. The change in the

pharmacokinetics of metformin can be explained on the basis of its decreased excretion by rabeprazole [70].

Hence caution needs to be observed while co-administering metformin with PPIs as this might reduce blood sugar more. It is known that metformin may produce gastritis which needs the co administration of PPIs to control this. One possibility needs to be considered while prescribing PPIs in cases of DM with gastro oesophageal reflux disorders [GERD] which has a common association in DM [71,72]. PPIs by relieving clinical symptoms of GERD can improve appetite despite the increased gastrin and decreased ghrelin levels and hence can derange glucose control in patients of DM. It is also reported that PPIs can induce dysbiosis, which is connected with metabolic syndrome [73].

PPIs through gastrin mechanism share the effects of incretin based therapies like glucoregulation, improvement in beta cell mass and function, slowing of gastric emptying, increase in satiety without weight gain. By inhibiting ghrelin release as a result of increased gastrin levels and through action on central nervous system PPIs help in reducing appetite. They do not produce hypoglycemia their glucose lowering effect is somewhat less than that by DPP 4 inhibitors and HbA1c reduction is in the range of 0.5-1% [74].

PPIs are considered to be safe and effective but like other drugs they also are not devoid of adverse drug reactions [ADRs]. These drugs given for long term can invite ADRs like hypo/achlorhydria, nutritional deficiencies of Vit B 12, calcium, magnesium and iron, acute interstitial nephritis, dementia, osteoporosis and fractures, enteric infections like clostridium difficile, pneumonias in ICU settings and increased incidence of myocardial ischemia. So monitoring of ADRs is needed while using these drugs for long term [75].

Thus PPIs can be considered as potential supportive therapy for DM mainly type2. Long term safety of these drugs needs to be confirmed by conducting clinical trials for prolonged duration. This will definitely encourage the use of PPIs in DM.

References

1. Van Dieren S, Beulens JW, Van der Schouw YT, Grobbee DE, Neal B (2010) The global burden of diabetes and its complications: an emerging pandemic. *Eur J Cardiovasc Prev Rehabil* 17(1): 3-8.

2. Irons BK, Minze MG (2014) Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated. *Diabetes Metab Syndr Obes* 7: 15-24.
3. DeFronzo RA (2009) From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. *Diabetes* 58(4): 773-795.
4. Shi S, Klotz U (2008) Proton pump inhibitors: an update of their clinical use and pharmacokinetics. *Eur J Clin Pharmacol* 64(10): 935-951.
5. Dockray G, Dimaline R, Varro A (2005) Gastrin: old hormone, new functions. *Pflugers Arch* 449(4): 344-355.
6. Gregory RA, Tracy HJ (1972) Isolation of two big gastrins from Zollinger Ellison tumour tissue. *Lancet* 2: 797-799.
7. Rehfeld JF (2011) Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides. *Acta Physiol (Oxf)* 201(4): 405-411.
8. Schubert ML, Makhlof GM (1993) Gastrin secretion induced by distention is mediated by gastric cholinergic and vasoactive intestinal peptide neurons in rats. *Gastroenterology* 104(3): 834-839.
9. Schubert ML, Makhlof GM (1992) Neural, hormonal, and paracrine regulation of gastrin and acid secretion. *Yale J Biol Med* 65(6): 553-560.
10. Chueca E, Lanas A, Piazuelo E (2012) Role of gastrin-peptides in Barrett's and colorectal carcinogenesis. *World J Gastroenterol* 18(45): 6560-6570.
11. Brand SJ, Stone D (1988) Reciprocal regulation of antral gastrin and somatostatin gene expression by omeprazole-induced achlorhydria. *J Clin Invest* 82(3): 1059-1066.
12. Burkitt MD, Varro A, Pritchard DM (2009) Importance of gastrin in the pathogenesis and treatment of gastric tumors. *World J Gastroenterol* 15(1): 1-16.
13. Gregory RA, Tracy HJ, Harris JI, Runswick MJ, Moore S, et al. (1979) Minigastrin; corrected structure and synthesis. *Hoppe Seylers Z Physiol Chem* 360(1): 73-80.
14. Dufresne M, Seva C, Fourmy D (2006) Cholecystokinin and gastrin receptors. *Physiol Rev* 86(3): 805-847.
15. Soll AH, Amirian DA, Thomas LP, Reedy TJ, Elashoff JD (1984) Gastrin receptors on isolated canine parietal cells. *J Clin Invest* 73(5): 1434-1447.
16. Bitziou E, Patel BA (2012) Simultaneous detection of gastric acid and histamine release to unravel the regulation of acid secretion from the guinea pig stomach. *Am J Physiol Gastrointest Liver Physiol* 303(3): 396-403.
17. Rooman I, Lardon J, Bouwens L (2002) Gastrin stimulates β -cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue. *Diabetes* 51(3): 686-690.
18. Suarez Pinzon WL, Yan Y, Power R, Brand SJ, Rabinovitch A (2005) Combination therapy with epidermal growth factor and gastrin increases β -cell mass and reverses hyperglycemia in diabetic NOD mice. *Diabetes* 54(9): 2596-2601.
19. Suarez Pinzon WL, Lakey JR, Brand SJ, Rabinovitch A (2005) Combination therapy with epidermal growth factor and gastrin induces neogenesis of human islet β -cells from pancreatic duct cells and an increase in functional β -cell mass. *J Clin Endocrinol Metab* 90(6): 3401-3409.
20. Hansen OH, Pedersen T, Larsen JK, Rehfeld JF (1946) Effect of gastrin on gastric mucosal cell proliferation in man. *Gut* 17(7): 536-541.
21. Tellez N, Joanny G, Escoriza J, Vilaseca M, Montanya E (2011) Gastrin treatment stimulates β -cell regeneration and improves glucose tolerance in 95% pancreatectomized rats. *Endocrinology* 152(7): 2580-2588.
22. Chen D, Zhao CM, Hakanson R, Samuelson LC, Rehfeld JF, et al. (2004) Altered control of gastric acid secretion in gastrin-cholecystokinin double mutant mice. *Gastroenterology* 126(2): 476-487.
23. Rehfeld F, Stadil F (1973) The effect of gastrin on basal- and glucose-stimulated insulin secretion in man. *J Clin Invest* 52(6): 1415-1426.
24. Crouch MA, Mefford IN, Wade EU (2012) Proton pump inhibitor therapy associated with lower glycosylated hemoglobin levels in type 2 diabetes. *J Am Board Fam Med* 25(1): 50-54.
25. Mefford IN, Mefford JT, Burriss CA (2012) Improved diabetes control and pancreatic function in a type 2

- diabetic after omeprazole administration. *Case Rep Endocrinol*.
26. Singh PK, Hota D, Dutta P, Sachdeva N, Chakrabarti A, et al. (2012) Pantoprazole improves glycemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled trial. *J Clin Endocrinol Metab* 97(11): 2105-2108.
 27. Mefford IN, Wade EU (2009) Proton pump inhibitors as a treatment method for type II diabetes. *Med. Hypotheses* 73(1): 29-32.
 28. Boj-Carceller D, Bocos-Terraz P, Moreno Vernis M, Sanz Paris A, Trincado Aznar P, et al. (2011) Are proton pump inhibitors a new antidiabetic drug? A cross sectional study. *World J Diabetes* 2(12): 217-220.
 29. Hove KD, Fxrch K, Bodvarsdottir TB, Karlsen AE, Petersen JS, et al. (2010) Treatment with a proton pump inhibitor improves glycaemic control in type 2 diabetic patients-a retrospective analysis. *Diabetes Res Clin Pract* 90(3): 72-74.
 30. Song SY, Gannon M, Washington MK, Scoggins CR, Meszoely IM, et al. (1999) Expansion of PDX-1-expressing pancreatic epithelium and islet neogenesis in transgenic mice overexpressing transforming growth factor α . *Gastroenterology* 117(6): 1416-1426.
 31. Yamamoto K, Miyagawa J, Waguri M, Sasada R, Igarashi K, et al. (2000) Recombinant human betacellulin promotes the neogenesis of β -cells and ameliorates glucose intolerance in mice with diabetes induced by selective alloxan perfusion. *Diabetes* 49(12): 2021-2027.
 32. Cras-Meneur C, Elghazi L, Czernichow P, Scharfmann R (2001) Epidermal growth factor increases undifferentiated pancreatic embryonic cells in vitro: a balance between proliferation and differentiation. *Diabetes* 50(7): 1571-1579.
 33. Krakowski ML, Kritzik MR, Jones EM, Krachl T, Lee J, et al. (1999) Transgenic expression of epidermal growth factor and keratinocyte growth factor in β -cells results in substantial morphological changes. *J Endocrinol* 162(2): 167-175.
 34. Xu G, Stoffers DA, Habener JF, Bonner-Weir S (1999) Exendin-4 stimulates both β -cell replication and neogenesis, resulting in increased β -cell mass and improved glucose tolerance in diabetic rats. *Diabetes* 48(12): 2270-2276.
 35. Brand SJ, Tagerud S, Lambert P, Magil SG, Tartarkiewicz K, et al. (2002) Pharmacological treatment of chronic diabetes by stimulating pancreatic β -cell regeneration with systemic co-administration of EGF and gastrin. *Pharmacol Toxicol* 91(6): 414-420.
 36. Rooman I, Bouwens L (2004) Combined gastrin and epidermal growth factor treatment induces islet regeneration and restores normoglycemia in C57BL6/J mice treated with alloxan. *Diabetologia* 47(2): 259-265.
 37. Suarez-Pinzon WL, Lakey JR, Rabinovitch A (2008) Combination therapy with glucagon-like peptide-1 and gastrin induces beta-cell neogenesis from pancreatic duct cells in human islets transplanted in immuno deficient diabetic mice. *Cell Transplant* 17(1): 631-640.
 38. Suarez-Pinzon WL, Power RL, Yan Y, Wasserfall C, Atkinson M, et al. (2008) Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. *Diabetes* 57(12): 3281-3288.
 39. Lugari R, Dei Cas A, Ugolotti D, Finardi L, Barilli AL, et al. (2002) Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non-insulin-dependent) diabetes. *Horm Metab Res* 34(3): 150-154.
 40. Suarez-Pinzon WL, Cembrowski GS, Rabinovitch A (2009) Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice. *Diabetologia* 52(8): 1680-1682.
 41. Sanaka M, Yamamoto T, Kuyama Y (2010) Effects of proton pump inhibitors on gastric emptying: a systematic review. *Dig Dis Sci* 55(9): 2431-2440.
 42. Tougas G, Earnest DL, Chen Y, Vanderkoy C, Rojavin M (2005) Omeprazole delays gastric emptying in healthy volunteers: an effect prevented by tegaserod. *Aliment Pharmacol Ther* 22(1): 59-65.
 43. Dammann HG, Burkhardt F (1999) Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion. *Eur J Gastroenterol Hepatol* 11(11): 1277-1282.

44. Crouch MA, Mefford IN, Wade EU (2012) Proton pump inhibitor therapy associated with lower glycosylated hemoglobin levels in type 2 diabetes. *J Am Board Fam Med* 25(1): 50-54.
45. Inci F, Atmaca M, Ozturk M, Yildiz S, Kocerogulu R, et al. (2014) Pantoprazole may improve beta cell function and diabetes mellitus. *J Endocrinol Invest* 37(5): 449-454.
46. Meier JJ, Butler AE, Galasso R, Rizza RA, Butler PC (2006) Increased islet beta cell replication adjacent to intrapancreatic gastrinomas in humans. *Diabetologia* 49(11): 2689-2696.
47. Sheen E, Triadafilopoulos G (2011) Adverse effects of long-term proton pump inhibitor therapy. *Dig Dis Sci* 56: 931-950.
48. Ligumsky M, Lysy J, Siguencia G, Friedlander Y (2001) Effect of long-term, continuous versus alternate-day omeprazole therapy on serum gastrin in patients treated for reflux esophagitis. *J Clin Gastroenterol* 33(1): 32-35.
49. Hu YM, Mei Q, Xu XH, Hu XP, Hu NZ, et al. (2006) Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans. *World J Gastroenterol* 12(29): 4750-4753.
50. Cadiot G, Vissuzaine C, Pospai D, Ruszniewski P, Potet F, et al. (1995) Effect of prolonged treatment with proton pump inhibitors on serum gastrin levels and the fundus mucosa Preliminary results. *Gastroenterol Clin Biol* 19(10): 811-817.
51. Koop H, Klein M, Arnold R (1990) Serum gastrin levels during long-term omeprazole treatment. *Aliment Pharmacol Ther* 4(2): 131-138.
52. Sanders SW, Tolman KG, Greski PA, Jennings DE, Hoyos PA, et al. (1992) The effects of lansoprazole, a new H⁺,K⁽⁺⁾-ATPase inhibitor, on gastric pH and serum gastrin. *Aliment Pharmacol Ther* 6(3): 359-372.
53. Sumii M, Sumii K, Tari A, Yoshihara M, Haruma K, et al. (1994) Regulation of antral peptides by administration of omeprazole to healthy men. *Am J Gastroenterol* 89(11): 2033-203.
54. Bødvarsdóttir TB, Hove KD, Gotfredsen CF, Pridal L, Vaag A, et al. (2010) Treatment with a proton pump inhibitor improves glycaemic control in Psammomysobesus, a model of type 2 diabetes. *Diabetologia* 53(10): 2220-2223.
55. Barchetta I, Guglielmi C, Bertocchini L, Calella D, Manfrini S, Secchi C, et al. (2015) Therapy with proton pump inhibitors in patients with type 2 diabetes is independently associated with improved glycometabolic control. *Acta Diabetol Epub Ahead of print* 52(5): 873-80.
56. González Ortiz M, MartínezAbundis E, Mercado Sesma AR, Álvarez Carrillo R (2015) Effect of pantoprazole on insulin secretion in drug-naïve patients with type 2 diabetes. *Diabetes Res ClinPract* 108(1): e11-e13.
57. Han N, Oh M, Park SM, Kim YJ, Lee EJ, et al. (2015) The effect of proton pump inhibitors on glycated hemoglobin levels in patients with type 2 diabetes mellitus. *Can J Diabetes* 39(1): 24-28.
58. Hove KD, Brøns C, Færch K, Lund SS, Petersen JS, et al. (2013) Effects of 12 weeks' treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study. *Diabetologia* 56(1): 22-30.
59. Rau TT, Sonst A, Rogler A, Burnat G, Neumann H, et al. (2013) Gastrin mediated down regulation of ghrelin and its pathophysiological role in atrophic gastritis. *J Physiol Pharmacol* 64(6): 719-725.
60. Clerc P, CollConstans MG, Lulka H, Broussaud S, Guigné C, et al. (2007) Involvement of cholecystokinin 2 receptor in food intake regulation: hyperphagia and increased fat deposition in cholecystokinin 2 receptor-deficient mice. *Endocrinology* 148(3): 1039-1049.
61. Greenstein RJ, Clain DJ, Straus E, Yalow RS (1987) Distribution, molecular forms, and bioactivity of immunoreactive gastrin in a patient with metastatic gastrinoma. *Am J Gastroenterol* 82(9): 886-889.
62. Banks WA, Audus KL, Davis TP (1992) Permeability of the blood-brain barrier to peptides: an approach to the development of therapeutically useful analogs. *Peptides* 13(6): 1289-1294.
63. Yakabi K, Iwabuchi H, Nakamura T, Endo K, Fukunaga Y, et al. (2002) Neuronal expression of Fos protein in the brain after intravenous injection of gastrin in rats. *Neurosci Lett* 317(2): 57-60.

64. Danzer M, Jovic M, Samberger C, Painsipp E, Bock E, et al. (2004) Stomach-brain communication by vagal afferents in response to luminal acid back diffusion, gastrin, and gastric acid secretion. *Am J Physiol Gastrointest Liver Physiol* 286(3): G403-G41.
65. Fan W, Ellacott KL, Halatchev IG, Takahashi K, Yu P, et al. (2004) Cholecystokinin-mediated suppression of feeding involves the brainstem melanocortin system. *Nat Neurosci* 7(4): 335-336.
66. Cao Y, Cao X, Liu XM (2015) Expression of cholecystokinin2-receptor in rat and human L cells and the stimulation of glucagon-like peptide-1 secretion by gastrin treatment. *Acta Histochem* 117(2): 205-210.
67. Nies AT, Hofmann U, Resch C, Schaeffeler E, Rius M, et al. (2011) Proton Pump Inhibitors Inhibit Metformin Uptake by Organic Cation Transporters (OCTs). *PLoS ONE* 6(7):e22163.
68. Kim A, Chung I, Yoon SH, Yu KS, Lim KS, Cho JY et al. (2014) Effects of proton pump inhibitors on metformin pharmacokinetics and pharmacodynamics. *Drug Metab Dispos* 42(7):1174-1179.
69. Ding Y, Jia Y, Song Y, Lu C, Li Y, et al. (2014) The effect of lansoprazole, an OCT inhibitor, on metformin pharmacokinetics in healthy subjects. *Eur J Clin Pharmacol* 70(2):141-146.
70. Liuab G, Wenab J, Guoa D, Wanga Z, Hua X, et al. (2016) The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers. *Journal of Pharmacological Sciences* 132(4): 244-248.
71. Feldman M, Schiller LR (1983) Disorders of gastrointestinal motility associated with diabetes mellitus. *Ann Intern Med* 98(3):378-384.
72. Maser RE, Pfeifer MA, Dorman JS, Kuller LH, Becker DJ, et al. (1990) Diabetic autonomic neuropathy and cardiovascular risk Pittsburgh Epidemiology of Diabetes Complications Study III. *Arch Intern Med* 150(6): 1218-1222.
73. Wallace JL, Syer S, Denou E, de Palma G, Vong L, et al. (2011) Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. *Gastroenterology* 141(4): 1314-1322.
74. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, et al. (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 35(6): 1364-1379.
75. Abraham NS (2012) Proton pump inhibitors: potential adverse effects. *Curr Opin Gastroenterol* 28(6): 615-620.

